No Data
No Data
Truist Financial Maintains Praxis Precision Medicines(PRAX.US) With Buy Rating
Praxis Precision Medicines (PRAX) Gets a Buy From Truist Financial
Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted For Relutrigine In Dravet Syndrome; Praxis Plans To Initiate An All-DEE Trial (EMERALD), Inclusive Of Dravet Syndrome, In 1H2025
Express News | Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome
9 Health Care Stocks With Whale Alerts In Today's Session
We're Not Very Worried About Praxis Precision Medicines' (NASDAQ:PRAX) Cash Burn Rate